Rizatriptan
- Generic Name
- Rizatriptan
- Brand Names
- Maxalt, Rizaport
- Drug Type
- Small Molecule
- Chemical Formula
- C15H19N5
- CAS Number
- 144034-80-0
- Unique Ingredient Identifier
- 51086HBW8G
- Background
Rizatriptan is a second-generation triptan and a selective 5-HT receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations.
- Indication
Rizatriptan is indicated for the acute treatment of diagnosed migraine with or without aura. Rizatriptan is not indicated for the prophylactic therapy of migraine nor the treatment of cluster headache.
...
- Associated Conditions
- Migraine With Aura, Migraine Without Aura, Migraine with acute onset aura
- Associated Therapies
- Acute Treatment of Migraine
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath